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OBJECTIVES: Transcription Factor 21 represses steroidogenic factor 1, a nuclear receptor required for gonadal
development, sex determination and the regulation of adrenogonadal steroidogenesis. The aim of this study
was to investigate whether silencing or overexpression of the gene Transcription Factor 21 could modulate the
gene and protein expression of steroidogenic factor 1 in adrenocortical tumors.
METHODS: We analyzed the gene expression of steroidogenic factor 1 using qPCR after silencing endogenous
Transcription Factor 21 in pediatric adrenal adenoma-T7 cells through small interfering RNA. In addition, using
overexpression of Transcription Factor 21 in human adrenocortical carcinoma cells, we analyzed the protein
expression of steroidogenic factor 1 using Western blotting.
RESULTS: Transcription Factor 21 knockdown increased the mRNA expression of steroidogenic factor 1 by
5.97-fold in pediatric adrenal adenoma-T7 cells. Additionally, Transcription Factor 21 overexpression inhibited
the protein expression of steroidogenic factor 1 by 0.41-fold and 0.64-fold in two different adult adrenocortical
carcinoma cell cultures, H295R and T36, respectively.
CONCLUSIONS: Transcription Factor 21 is downregulated in adrenocortical carcinoma cells. Taken together, these
findings support the hypothesis that Transcription Factor 21 is a regulator of steroidogenic factor 1 and is a tumor
suppressor gene in pediatric and adult adrenocortical tumors.
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’ INTRODUCTION
Transcription Factor 21 (Tcf21, POD1, capsulin, epicardin)
is a basic helix-loop-helix (bHLH) transcriptional regulatory
protein that is expressed in mesenchymal cells (1) at sites
of mesenchymal-epithelial interaction in the developing
urogenital (2), cardiovascular, respiratory, and gastrointest-
inal systems (3). In the adrenal gland, POD1 is expressed
exclusively in the capsule region of the adrenal cortex, as
shown in mice expressing a lacZ gene reporter under the
control of the regulatory region of Pod1 (4). In the testicles of
fetal mice, POD1 represses steroidogenic factor 1 (SF-1/Nr5a1),
an orphan member of the nuclear receptor family of transcrip-
tion factors required for gonadal development, sex determina-
tion and the regulation of adrenal and gonadal steroidogenesis
in adult mice (5). Alterations of SF-1 dosage regulate compen-
satory adrenal growth after unilateral adrenalectomy,
proliferation and tumorigenesis in mice (6). In humans, SF-1
is associated with adrenocortical tumorigenesis both in
children (7) and adults (8). POD1 represses Sf-1/SF-1/SF-1
expression in mouse (5), rat (9), and human adrenocortical
cells (10). Moreover, POD1 is downregulated in adrenocor-
tical carcinoma (ACC) (10,11), melanoma (12), lung, and
head and neck squamous cell carcinomas (13). In human
ACC cells, we showed that POD1 binds to the SF-1 E-box
promoter sequence and inhibits SF-1 expression and ster-
oidogenic acute regulatory (StAR) expression, which is
controlled by SF-1 (10). However, it is unknown whether
silencing the POD1 gene promotes increased expression of
the SF-1 gene. Accordingly, here, we analyzed the expression
of the SF-1 gene after downregulation of endogenous POD1
expression in pediatric adrenocortical tumor cells. Moreover,
we verified whether POD1 overexpression causes inhibition
of SF-1 protein expression.
’ MATERIALS AND METHODS
Cell cultures and cell culture transfection
The NCI-H295R adult human ACC cell line (14) and ACC-
T36 (10), a 6th–10th passage secondary adult human ACC cell
line, were cultured and transfected as described by Franc¸a
et al. (10). Cells from the ACA-T7 pediatric secondary cellDOI: 10.6061/clinics/2017(06)10
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line were obtained from a functioning adrenocortical adenoma
(ACA) as described by Almeida et al. (15). Pediatric adenoma
(weight: 10 g; stage I) was diagnosed in a 1.1-yr-old girl with
mixed Cushing’s syndrome and virilization (15). The adreno-
cortical tumor cells were maintained at 37oC in a fully humid-
ified 95% air-5% CO2 environment and cultured in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin.
The experiments were performed at the 10th–15th passage of the
pediatric ACA culture cells. Briefly, 1.5 x 105 ACA-T7 cells were
plated into six-well tissue culture plates (Becton Dickinson
Labware, Franklin Lakes, NJ, USA). After 24 h, the cells were
transfected with small interfering RNA (siRNA-POD1) or posi-
tive or negative high CG RNAi Stealth (Invitrogen, Carlsbad,
CA, USA) to a final concentration of 100 nM, combined with
9 ml of RNAiMax Lipofectamines according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA, USA).
Total RNA extraction and qPCR siRNA (qRT-PCR)
Total RNAwas extracted using TRIzols reagent (Invitrogen)
48 h after transfection. The synthesis of cDNA and RT-qPCR
analysis were performed as described by Franc¸a et al. (10).
A cycle threshold (Ct) value in the log-linear phase of ampli-
fication was selected for each sample in triplicate and was
normalized to the b-actin expression level. Reactions were
conducted in triplicate. Data were analyzed using the 2-DDCt
method (16).
Figure 1 - A and B: Immunoblotting analysis of the SF-1 protein levels relative to a-Actin in H295R (A) and ACC-T36 cells (B) that were
transiently transfected with pCMVMycPod1 or empty pCMVMyc vectors. C and D: Quantitative reverse transcription PCR (qRT-PCR)
analysis of the mRNA expression levels of POD1 (C) and SF1 (D) relative to b-Actin in ACA-T7 pediatric adrenocortical adenoma culture
cells. The expression levels were compared using paired t-tests (A and B) or one-way ANOVA Kruskal-Wallis tests (C and D). The values
represent the mean ± standard deviation of three experiments.
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Immunoblotting
For the protein assay, H295R and ACC-T36 cells were plated
and transfected as described by Franc¸a et al. (17). The cells
were lysed 72 h post-transfection in RIPA buffer containing
protease and phosphatase inhibitors (Sigma Aldrich Gmbh,
Steinheim, Germany). The total protein concentration was
determined using the Bradford assay. Total protein lysates
(30 mg) were resolved by 12% SDS-PAGE and gels were
blotted onto nitrocellulose membranes after electrophoresis.
Non-specific binding sites were blocked for 2 h with 0.1%
bovine serum albumin (BSA) or 5% non-fat dried milk in
TBST (TRIS-buffered saline solution containing 1% Tween 20).
All washes and antibody incubations were performed using
TBST. The following primary antibodies were used: anti-SF-1
(RD Systems Inc., Minneapolis, MN, USA; 1:1000) in blocking
buffer (5% non-fat dried milk in TBST) and anti-actin (1:1000)
in TRIS-buffered saline containing 1% Tween 20. Proteins were
visualized using enhanced chemiluminescence (ECL) detec-
tion with secondary HRP-conjugated anti-rabbit (Amersham
Hybond ECL, Freiburg, Germany) or anti-mouse (Jackson
ImmunoResearch Inc., West Grove, PA, USA) antibodies.
Immunoblot results were quantified on a densitometer using
GeneSnap and GeneTools software (SynGene-Synoptic Ltd.,
Cambridge, United Kingdom). Protein transfer and loading
were monitored using Ponceau S staining of the membranes.
The experiments were repeated in full at least three times,
and SF-1 protein expression was normalized to the levels of
b-actin.
Statistical analysis
Data are presented as the mean± standard deviation (SD)
of three independent replicate experiments. Data were analyzed
using the Kruskal-Wallis test (non-parametric one-way
ANOVA) or paired t-tests, when indicated. The results
were considered significant when po0.05.
’ RESULTS AND DISCUSSION
SF-1 protein levels in the H295R cell line (Figure 1A)
decreased 0.41±0.11-fold (p=0.004) compared to those in the
empty plasmid controls, whereas in ACC-T36 cells (Figure 1B),
SF-1 protein expression decreased 0.64±0.22-fold (p=0.05).
These results are in agreement with a previous study show-
ing that POD1 inhibited SF-1mRNA expression in ACC cells
(10). Next, we investigated whether knockdown of POD1
could increase SF-1 expression. To knockdown POD1, we
used siRNA in ACA-T7 cells that expressed POD1 constitu-
tively (data not shown) and determined the mRNA levels
of POD1 and SF-1 in ACA-T7-siRNA-transfected and ACA-
T7-siPOD1-transfected cells. POD1 mRNA expression was
significantly lower in T7-siPOD1 transfected cells (0.35±
0.22-fold), with a 65% decrease compared to that in trans-
fected controls (ANOVA, p=0.001; Figure 1C), whereas the
mRNA levels of SF1 increased 5.97±0.22-fold in T7-siPOD-1
cells compared to those in transfected controls (ANOVA,
p=0.05; Figure 1D). These results support a role for POD1/
TCF21 as a regulator of SF-1 expression in adrenocortical
tumor cells. Considering that POD1 is a repressor of SF-1
expression, that increased SF-1 dosage can trigger human
adrenocortical cell proliferation (18), and that SF1 amplifica-
tion (19) and SF1 overexpression (7) are characteristic of child-
hood adrenocortical tumors, the results of our study improve
the knowledge of how the tumorigenic process is controlled in
adrenocortical tumor cells. Taken together, the findings of this
study and the POD1 inactivation observed in several types of
tumors suggest that POD1 may act as a tumor suppressor in
pediatric and adult adrenocortical tumors.
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